血友病治疗市场－全球产业规模、份额、趋势、机会及预测（按类型、产品、治疗方法、疗法、地区和竞争格局划分），2021-2031年

全球血友病治疗市场预计将从 2025 年的 120.3 亿美元成长到 2031 年的 168.2 亿美元，复合年增长率为 5.75%。

治疗方法包括替代疗法，例如重组凝血因子和血浆衍生凝血因子，以及纠正因子VIII或IX缺乏的非因子疗法。市场成长的主要驱动力是全球患者识别率的提高以及向需要持续用药的预防性护理模式的转变。根据世界血友病联盟（WFH）预测，到2023年，全球确诊的血友病患者将达到218,804人，随着医疗系统日益重视出血性疾病的长期管理，这将为持续的治疗需求奠定坚实的基础。

然而，先进治疗方案的高昂成本对市场扩张构成重大障碍。重组凝血因子和创新治疗方法的高价造成了严重的进入门槛，尤其是在中低收入国家，这些国家的健保报销体系往往不完善。这种经济差距限制了发展中地区的潜在市场，并且仍然是寻求全球扩张的製造商面临的一大障碍。

市场驱动因素

新型基因疗法和根治性治疗方法的引入是推动全球血友病治疗格局变革的主要动力，促使治疗重点从慢性疾病管理转向一次性治疗方法。这项变革的标誌是高价值治疗方法的核准，这些疗法只需单次给药即可长期预防出血，从而改变了支付模式和长期收入前景。支持这一价值转变的关键市场趋势是新核准的基因疗法 Beqvez 的上市，根据 Fierce Pharma 2024 年 4 月发表的题为「辉瑞获得 FDA核准的B型血友病基因疗法」的报导，该疗法的定价为 350 万美元。儘管需要大量的初始投资，但这些治疗方法引起了医疗系统的极大兴趣，他们希望减轻与严重出血性疾病相关的终身经济负担。

同时，非因子替代疗法的快速普及正在透过减轻患者的治疗负担，彻底改变标准的预防性护理模式。市场正经历从静脉注射凝血因子疗法到皮下注射双特异性抗体疗法的重大转变，后者可在减少给药频率的同时提供持续疗效。强劲的财务业绩也支撑了这一趋势。根据罗氏公司于2024年2月发布的《2023年财务报告》，非因子疗法Hemlibra的年销售额预计将达到41.47亿瑞士法郎，凸显了其在预防性护理领域的领先地位。儘管非因子疗法不断扩展，但整体治疗需求依然庞大。根据世界血友病联盟于2024年10月发布的《2023年全球年度调查报告》，全球VIII因子浓缩物的消耗量估计约为94亿国际单位，显示全球治疗需求规模依然庞大。

市场挑战

先进治疗方案的高昂费用严重阻碍了全球血友病治疗市场的成长。重组凝血因子和新型基因疗法的高昂价格对许多发展中国家的医疗体系造成了难以克服的财务障碍。在公共健保体系薄弱或缺乏的国家，这些救命疗法对大多数患者而言仍然遥不可及。这种经济差距严重限制了製药企业的商业性拓展，迫使它们依赖饱和的高所得市场，而新兴经济体庞大的需求却因经济限製而无法满足。

这种经济差距的后果在治疗产品全球分布不均中体现得淋漓尽致。根据世界血友病联盟的数据，2023年高高所得国家占全球整体VIII因子使用量的61%，而低收入国家仅占0.3%。这种显着的不平衡表明，儘管诊断率不断上升，低收入国家无力承担高昂的治疗费用，人为地限制了市场潜力。因此，该行业无法将不断增长的全球患者群体转化为实际的收入，阻碍了整体市场扩张。

市场趋势

随着非因子疗法的兴起，延长半衰期VIII因子疗法的普及正在积极重塑血友病领域的竞争格局，并再次凸显了因子替代疗法的重要性。这一趋势包括采用新一代融合蛋白，这些融合蛋白可显着延长循环VIII因子的半衰期，使患者能够在减少给药频率的同时维持持续的高因子活性。这项变更带来的直接商业性影响体现在近期核准的、每週只需给药一次即可维持最高保护水准的药物的快速市场渗透。根据赛诺菲2024年10月发布的新闻稿《赛诺菲2024年第三季业绩》，仅在第三季度，延长半衰期VIII因子疗法Altubio的销售额就达到了1.72亿欧元，这主要得益于患者从标准因子疗法和其他疗法转而使用Altubio。

随着凝血因子替代疗法的不断发展，新型RNA干扰疗法也取得了进展，其独特的作用机制从根本上针对凝血级联反应。与替代因子或双特异性抗体不同，这些研究治疗方法利用小干扰RNA抑制抗凝血酶的产生，有效平衡A型血友病患者的止血功能，且不受抑制剂状态的影响。该方法旨在透过基材的途径实现持续的止血，标誌着与传统蛋白质替代疗法的转变。新兴的临床数据支持了此作用机制的准确性。根据赛诺菲公司2024年6月发布的关于ISTH会议报告的新闻稿，3期临床试验结果显示，该RNAi疗法透过将抗凝血酵素活性维持在15%至35%之间，实现了具有临床意义的出血控制。

目录

第一章概述

第二章调查方法

第三章执行摘要

第四章：客户评价

第五章 全球血友病治疗市场展望

• 市场规模及预测
  • 按金额
• 市占率及预测
  • 按类型（A型血友病A、B型血友病、血友病C）
  • 副产品（重组凝血因子浓缩物、血浆衍生凝血因子浓缩物、去氨加压素、抗纤溶药物）
  • 透过治疗（按需和预防）
  • 透过治疗（替代疗法、即时治疗（ITI）疗法、基因疗法）
  • 按地区
  • 按公司（2025 年）
• 市场地图

第六章：北美血友病治疗市场展望

• 市场规模及预测
• 市占率及预测
• 北美洲：国家分析
  • 我们
  • 加拿大
  • 墨西哥

7. 欧洲血友病治疗市场展望

• 市场规模及预测
• 市占率及预测
• 欧洲：国家分析
  • 德国
  • 法国
  • 英国
  • 义大利
  • 西班牙

8. 亚太地区血友病治疗市场展望

• 市场规模及预测
• 市占率及预测
• 亚太地区：国家分析
  • 中国
  • 印度
  • 日本
  • 韩国
  • 澳洲

9. 中东和非洲血友病治疗市场展望

• 市场规模及预测
• 市占率及预测
• 中东和非洲：国家分析
  • 沙乌地阿拉伯
  • 阿拉伯聯合大公国
  • 南非

第十章：南美洲血友病治疗市场展望

• 市场规模及预测
• 市占率及预测
• 南美洲：国家分析
  • 巴西
  • 哥伦比亚
  • 阿根廷

第十一章 市场动态

• 司机
• 任务

第十二章 市场趋势与发展

• 併购
• 产品发布
• 最新进展

第十三章 全球血友病治疗市场：SWOT分析

第十四章 波特五力分析

• 产业竞争
• 新进入者的可能性
• 供应商电力
• 顾客权力
• 替代品的威胁

第十五章 竞争格局

• Bayer AG
• BioMarin Pharmaceutical, Inc.
• CSL Behring LLC
• Kedrion SpA
• Novo Nordisk A/S
• Pfizer, Inc.
• Octapharma AG
• Sanofi SA
• Takeda Pharmaceutical Company Limited
• Grifols SA

第十六章 策略建议

第十七章：关于研究公司及免责声明

The Global Haemophilia Treatment Market is projected to expand from USD 12.03 Billion in 2025 to USD 16.82 Billion by 2031, registering a CAGR of 5.75%. Treatment methodologies include replacement therapies, such as recombinant and plasma-derived clotting factors, as well as non-factor agents aimed at correcting deficiencies in Factor VIII or IX. Market growth is primarily fueled by improved global patient identification and a transition toward prophylactic care models that require consistent product administration. According to the World Federation of Hemophilia, the global population of identified haemophilia patients was reported as 218,804 in 2023, creating a solid foundation for sustained therapeutic demand as healthcare systems place greater emphasis on the long-term management of bleeding disorders.

However, market expansion faces a substantial obstacle due to the prohibitive costs of advanced therapeutic options. The high pricing of recombinant factors and innovative therapies creates significant accessibility barriers, especially in low- and middle-income countries where reimbursement structures are frequently inadequate. This economic disparity limits the addressable market within developing regions and remains a critical hurdle for manufacturers seeking to extend their global footprint.

Market Driver

The introduction of novel gene therapies and curative solutions is a major driver transforming the global haemophilia treatment landscape, shifting the focus from chronic disease management to potential one-time cures. This evolution is defined by the approval of high-value treatments offering long-term bleed protection through a single administration, which subsequently alters payer models and long-term revenue outlooks. A key market development underscores this value shift; as reported by Fierce Pharma in April 2024 in the article 'Pfizer scores FDA nod for hemophilia B gene therapy', the newly approved gene therapy Beqvez launched with a list price of $3.5 million. Despite the substantial upfront investment, such therapies are attracting significant interest from healthcare systems seeking to reduce the lifetime economic burden associated with severe bleeding disorders.

Simultaneously, the rapid adoption of non-factor replacement therapies is revolutionizing standard prophylactic care by lowering the treatment burden for patients. The market is witnessing a decisive move from intravenous clotting factors to subcutaneous bispecific antibodies that provide reduced dosing frequency and consistent efficacy. This trend is supported by strong financial performance; according to Roche's 'Finance Report 2023' released in February 2024, full-year sales of the non-factor therapy Hemlibra reached CHF 4,147 million, highlighting its dominance in prophylactic settings. While non-factor agents are expanding, overall therapeutic demand remains massive; the World Federation of Hemophilia's 'Report on the Annual Global Survey 2023', published in October 2024, indicated that global consumption of Factor VIII concentrates was approximately 9.4 billion IU, emphasizing the sustained scale of worldwide therapeutic requirements.

Market Challenge

The prohibitive costs associated with advanced therapeutic options constitute a formidable barrier to the growth of the global haemophilia treatment market. The high price tags on recombinant clotting factors and novel gene therapies create a steep financial threshold that many healthcare systems in developing regions cannot overcome. In nations where public reimbursement frameworks are insufficient or nonexistent, these life-saving treatments remain largely inaccessible to the majority of the patient population. This economic disconnect severely restricts the commercial reach of pharmaceutical manufacturers, compelling them to rely heavily on saturated high-income markets while leaving substantial demand in emerging economies unaddressed due to affordability constraints.

The consequences of this economic disparity are clearly visible in the uneven global distribution of treatment products. Data from the World Federation of Hemophilia indicates that in 2023, high-income countries were responsible for 61% of total global Factor VIII usage, whereas low-income countries contributed a mere 0.3% to global consumption. This stark imbalance demonstrates that, despite rising diagnosis rates, the market's potential is artificially capped by the inability of lower-income nations to purchase premium therapeutics. Consequently, the industry struggles to convert the growing global patient pool into tangible revenue, thereby hampering overall market expansion.

Market Trends

The widespread adoption of Extended Half-Life Factor Concentrates is actively reshaping the competitive dynamics of the haemophilia sector by renewing the relevance of factor replacement therapies amidst the rise of non-factor alternatives. This trend involves the uptake of next-generation fusion proteins that significantly extend the circulating half-life of Factor VIII, enabling patients to maintain high sustained factor activity with reduced injection frequency. The immediate commercial impact of this shift is evident in the rapid market penetration of recently approved agents that offer once-weekly dosing while preserving peak protection levels. According to Sanofi's 'Press Release: Sanofi Q3 2024' from October 2024, sales of the extended half-life therapy Altuviiio reached €172 million in the third quarter alone, driven primarily by patients switching from standard factor regimens and other therapeutics.

Parallel to the evolution of factor replacement, the advancement in Novel RNA Interference Therapeutics is introducing a distinct mechanism of action that targets the coagulation cascade at a fundamental level. Unlike replacement factors or bispecific antibodies, these investigational therapies utilize small interfering RNA to suppress antithrombin production, effectively rebalancing hemostasis for patients with either Haemophilia A or B, regardless of inhibitor status. This approach aims to provide consistent bleed protection through a substrate-independent pathway, marking a departure from traditional protein replacement strategies. New clinical data supports this mechanism's precision; according to Sanofi's June 2024 press release regarding ISTH presentations, phase 3 study results demonstrated that maintaining antithrombin activity levels between 15% and 35% via this RNAi therapy resulted in clinically meaningful bleed control for patients.

Key Market Players

• Bayer AG
• BioMarin Pharmaceutical, Inc.
• CSL Behring LLC
• Kedrion S.p.A
• Novo Nordisk A/S
• Pfizer, Inc.
• Octapharma AG
• Sanofi SA
• Takeda Pharmaceutical Company Limited
• Grifols S.A.

Report Scope

In this report, the Global Haemophilia Treatment Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Haemophilia Treatment Market, By Type

• Haemophilia A
• Haemophilia B
• Haemophilia C

Haemophilia Treatment Market, By Product

• Recombinant Coagulation Factor Concentrates
• Plasma Derived Coagulation Factor Concentrate
• Desmopressin
• Antifibrinolytics Agents

Haemophilia Treatment Market, By Treatment

• On-demand and Prophylaxis

Haemophilia Treatment Market, By Therapy

• Replacement Therapy
• ITI therapy and Gene Therapy

Haemophilia Treatment Market, By Region

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
• Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Haemophilia Treatment Market.

Available Customizations:

Global Haemophilia Treatment Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Haemophilia Treatment Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Type (Haemophilia A, Haemophilia B, Haemophilia C)
  • 5.2.2. By Product (Recombinant Coagulation Factor Concentrates, Plasma Derived Coagulation Factor Concentrate, Desmopressin, Antifibrinolytics Agents)
  • 5.2.3. By Treatment (On-demand and Prophylaxis)
  • 5.2.4. By Therapy (Replacement Therapy, ITI therapy and Gene Therapy)
  • 5.2.5. By Region
  • 5.2.6. By Company (2025)
• 5.3. Market Map

6. North America Haemophilia Treatment Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Type
  • 6.2.2. By Product
  • 6.2.3. By Treatment
  • 6.2.4. By Therapy
  • 6.2.5. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States Haemophilia Treatment Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Type
      • 6.3.1.2.2. By Product
      • 6.3.1.2.3. By Treatment
      • 6.3.1.2.4. By Therapy
  • 6.3.2. Canada Haemophilia Treatment Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Type
      • 6.3.2.2.2. By Product
      • 6.3.2.2.3. By Treatment
      • 6.3.2.2.4. By Therapy
  • 6.3.3. Mexico Haemophilia Treatment Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Type
      • 6.3.3.2.2. By Product
      • 6.3.3.2.3. By Treatment
      • 6.3.3.2.4. By Therapy

7. Europe Haemophilia Treatment Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Type
  • 7.2.2. By Product
  • 7.2.3. By Treatment
  • 7.2.4. By Therapy
  • 7.2.5. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. Germany Haemophilia Treatment Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Type
      • 7.3.1.2.2. By Product
      • 7.3.1.2.3. By Treatment
      • 7.3.1.2.4. By Therapy
  • 7.3.2. France Haemophilia Treatment Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Type
      • 7.3.2.2.2. By Product
      • 7.3.2.2.3. By Treatment
      • 7.3.2.2.4. By Therapy
  • 7.3.3. United Kingdom Haemophilia Treatment Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Type
      • 7.3.3.2.2. By Product
      • 7.3.3.2.3. By Treatment
      • 7.3.3.2.4. By Therapy
  • 7.3.4. Italy Haemophilia Treatment Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Type
      • 7.3.4.2.2. By Product
      • 7.3.4.2.3. By Treatment
      • 7.3.4.2.4. By Therapy
  • 7.3.5. Spain Haemophilia Treatment Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Type
      • 7.3.5.2.2. By Product
      • 7.3.5.2.3. By Treatment
      • 7.3.5.2.4. By Therapy

8. Asia Pacific Haemophilia Treatment Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Type
  • 8.2.2. By Product
  • 8.2.3. By Treatment
  • 8.2.4. By Therapy
  • 8.2.5. By Country
• 8.3. Asia Pacific: Country Analysis
  • 8.3.1. China Haemophilia Treatment Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Type
      • 8.3.1.2.2. By Product
      • 8.3.1.2.3. By Treatment
      • 8.3.1.2.4. By Therapy
  • 8.3.2. India Haemophilia Treatment Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Type
      • 8.3.2.2.2. By Product
      • 8.3.2.2.3. By Treatment
      • 8.3.2.2.4. By Therapy
  • 8.3.3. Japan Haemophilia Treatment Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Type
      • 8.3.3.2.2. By Product
      • 8.3.3.2.3. By Treatment
      • 8.3.3.2.4. By Therapy
  • 8.3.4. South Korea Haemophilia Treatment Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Type
      • 8.3.4.2.2. By Product
      • 8.3.4.2.3. By Treatment
      • 8.3.4.2.4. By Therapy
  • 8.3.5. Australia Haemophilia Treatment Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Type
      • 8.3.5.2.2. By Product
      • 8.3.5.2.3. By Treatment
      • 8.3.5.2.4. By Therapy

9. Middle East & Africa Haemophilia Treatment Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Type
  • 9.2.2. By Product
  • 9.2.3. By Treatment
  • 9.2.4. By Therapy
  • 9.2.5. By Country
• 9.3. Middle East & Africa: Country Analysis
  • 9.3.1. Saudi Arabia Haemophilia Treatment Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Type
      • 9.3.1.2.2. By Product
      • 9.3.1.2.3. By Treatment
      • 9.3.1.2.4. By Therapy
  • 9.3.2. UAE Haemophilia Treatment Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Type
      • 9.3.2.2.2. By Product
      • 9.3.2.2.3. By Treatment
      • 9.3.2.2.4. By Therapy
  • 9.3.3. South Africa Haemophilia Treatment Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Type
      • 9.3.3.2.2. By Product
      • 9.3.3.2.3. By Treatment
      • 9.3.3.2.4. By Therapy

10. South America Haemophilia Treatment Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Type
  • 10.2.2. By Product
  • 10.2.3. By Treatment
  • 10.2.4. By Therapy
  • 10.2.5. By Country
• 10.3. South America: Country Analysis
  • 10.3.1. Brazil Haemophilia Treatment Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Type
      • 10.3.1.2.2. By Product
      • 10.3.1.2.3. By Treatment
      • 10.3.1.2.4. By Therapy
  • 10.3.2. Colombia Haemophilia Treatment Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Type
      • 10.3.2.2.2. By Product
      • 10.3.2.2.3. By Treatment
      • 10.3.2.2.4. By Therapy
  • 10.3.3. Argentina Haemophilia Treatment Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Type
      • 10.3.3.2.2. By Product
      • 10.3.3.2.3. By Treatment
      • 10.3.3.2.4. By Therapy

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Merger & Acquisition (If Any)
• 12.2. Product Launches (If Any)
• 12.3. Recent Developments

13. Global Haemophilia Treatment Market: SWOT Analysis

14. Porter's Five Forces Analysis

• 14.1. Competition in the Industry
• 14.2. Potential of New Entrants
• 14.3. Power of Suppliers
• 14.4. Power of Customers
• 14.5. Threat of Substitute Products

15. Competitive Landscape

• 15.1. Bayer AG
  • 15.1.1. Business Overview
  • 15.1.2. Products & Services
  • 15.1.3. Recent Developments
  • 15.1.4. Key Personnel
  • 15.1.5. SWOT Analysis
• 15.2. BioMarin Pharmaceutical, Inc.
• 15.3. CSL Behring LLC
• 15.4. Kedrion S.p.A
• 15.5. Novo Nordisk A/S
• 15.6. Pfizer, Inc.
• 15.7. Octapharma AG
• 15.8. Sanofi SA
• 15.9. Takeda Pharmaceutical Company Limited
• 15.10. Grifols S.A.

16. Strategic Recommendations

17. About Us & Disclaimer